SCHEMBL23701439

SCHEMBL23701439

CS(=O)(=O)N1CCN(c2ccc(N3CC4CN(C(=O)O)CC4C3)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
RAB9A P51151 4/20 0.52
NPC1 O15118 3/20 0.52
POLB P06746 2/20 0.51
ALDH1A1 P00352 4/20 0.49
GAA P10253 1/20 0.49
KDM4E B2RXH2 3/20 0.47
LMNA P02545 1/20 0.45
THRB P10828 1/20 0.45
TSHR P16473 2/20 0.44
CYP2C9 P11712 1/20 0.44
GLA P06280 1/20 0.44
TP53 P04637 1/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
EED O75530 1/20 0.43
RORC P51449 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23732384 0.82 GPR119 (0.58) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL23701370 0.82 GAA (0.52) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL23701372 0.82 GAA (0.52) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL23701481 0.82 GPR119 (0.58) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL20907387 0.81 MAPT (0.44) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL23701440 0.80 GAA (0.47) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL27400156 0.80 GAA (0.53) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL23701441 0.80 GAA (0.47) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL20510814 0.79 AKR1C3 (0.44) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL23701474 0.78 MAPT (0.50) MAPTSMN1; SMN2MEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018029-B2 Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2024-06-25 US disclosed
US-20210238179-A1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018029-B2 Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors LOX, LOXL1, LOXL3 MAPT 4829/4885SMN1; SMN2 3383/4885MEN1 4448/4885
US-20210238179-A1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS LOX, LOXL1, LOXL3 MAPT 4829/4885SMN1; SMN2 3383/4885MEN1 4448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.